Potential harms associated with 4-aminoquinoline treatment
Hydroxychloroquine and chloroquine are currently being evaluated as treatment against COVID-19. These drugs are associated with some potential harms, including QTc-interval prolongation, hypoglycaemia, severe skin reactions and psychiatric effects. Use of hydroxychloroquine or chloroquine should be...
Gespeichert in:
| Veröffentlicht in: | Läkartidningen 2020-04, Vol.117 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | swe |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | Läkartidningen |
| container_volume | 117 |
| creator | Svensson, Markus |
| description | Hydroxychloroquine and chloroquine are currently being evaluated as treatment against COVID-19. These drugs are associated with some potential harms, including QTc-interval prolongation, hypoglycaemia, severe skin reactions and psychiatric effects. Use of hydroxychloroquine or chloroquine should be reserved to current indications or clinical trials, as recommended by several governmental medical products agencies. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_32365215</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32365215</sourcerecordid><originalsourceid>FETCH-LOGICAL-p565-47257387d86f11e0297b1958ba8dcaf8f3e16d1b2968dc9db0bb2ed64f1042543</originalsourceid><addsrcrecordid>eNo1j9tKAzEYhIMgtlZfQfICgfw5r3dSPEFBL3pf_jQJjWx2102K-PYuqDczMB8zMBdkDUYLZjW4Fbmu9YNz7gznV2QlhVwQ6DW5fx9bHFrGnp5wLpVireMxY4uBfuV2oophycP4eV6kz0OkbY7YytK5IZcJ-xpv_3xD9k-P--0L2709v24fdmzSRjNlhbbS2eBMAohcdNZDp51HF46YXJIRTAAvOrMEXfDcexGDUQm4ElrJDbn7nZ3OvsRwmOZccP4-_H-QP2xkQeE</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Potential harms associated with 4-aminoquinoline treatment</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Svensson, Markus</creator><creatorcontrib>Svensson, Markus</creatorcontrib><description>Hydroxychloroquine and chloroquine are currently being evaluated as treatment against COVID-19. These drugs are associated with some potential harms, including QTc-interval prolongation, hypoglycaemia, severe skin reactions and psychiatric effects. Use of hydroxychloroquine or chloroquine should be reserved to current indications or clinical trials, as recommended by several governmental medical products agencies.</description><identifier>EISSN: 1652-7518</identifier><identifier>PMID: 32365215</identifier><language>swe</language><publisher>Sweden</publisher><subject>Aminoquinolines - adverse effects ; Aminoquinolines - therapeutic use ; Antimalarials - adverse effects ; Antiviral Agents - adverse effects ; Betacoronavirus ; Chloroquine - adverse effects ; Coronavirus Infections - drug therapy ; COVID-19 ; Humans ; Hydroxychloroquine - adverse effects ; Pandemics ; Pneumonia, Viral - drug therapy ; SARS-CoV-2</subject><ispartof>Läkartidningen, 2020-04, Vol.117</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32365215$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Svensson, Markus</creatorcontrib><title>Potential harms associated with 4-aminoquinoline treatment</title><title>Läkartidningen</title><addtitle>Lakartidningen</addtitle><description>Hydroxychloroquine and chloroquine are currently being evaluated as treatment against COVID-19. These drugs are associated with some potential harms, including QTc-interval prolongation, hypoglycaemia, severe skin reactions and psychiatric effects. Use of hydroxychloroquine or chloroquine should be reserved to current indications or clinical trials, as recommended by several governmental medical products agencies.</description><subject>Aminoquinolines - adverse effects</subject><subject>Aminoquinolines - therapeutic use</subject><subject>Antimalarials - adverse effects</subject><subject>Antiviral Agents - adverse effects</subject><subject>Betacoronavirus</subject><subject>Chloroquine - adverse effects</subject><subject>Coronavirus Infections - drug therapy</subject><subject>COVID-19</subject><subject>Humans</subject><subject>Hydroxychloroquine - adverse effects</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>SARS-CoV-2</subject><issn>1652-7518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j9tKAzEYhIMgtlZfQfICgfw5r3dSPEFBL3pf_jQJjWx2102K-PYuqDczMB8zMBdkDUYLZjW4Fbmu9YNz7gznV2QlhVwQ6DW5fx9bHFrGnp5wLpVireMxY4uBfuV2oophycP4eV6kz0OkbY7YytK5IZcJ-xpv_3xD9k-P--0L2709v24fdmzSRjNlhbbS2eBMAohcdNZDp51HF46YXJIRTAAvOrMEXfDcexGDUQm4ElrJDbn7nZ3OvsRwmOZccP4-_H-QP2xkQeE</recordid><startdate>20200423</startdate><enddate>20200423</enddate><creator>Svensson, Markus</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20200423</creationdate><title>Potential harms associated with 4-aminoquinoline treatment</title><author>Svensson, Markus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p565-47257387d86f11e0297b1958ba8dcaf8f3e16d1b2968dc9db0bb2ed64f1042543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>swe</language><creationdate>2020</creationdate><topic>Aminoquinolines - adverse effects</topic><topic>Aminoquinolines - therapeutic use</topic><topic>Antimalarials - adverse effects</topic><topic>Antiviral Agents - adverse effects</topic><topic>Betacoronavirus</topic><topic>Chloroquine - adverse effects</topic><topic>Coronavirus Infections - drug therapy</topic><topic>COVID-19</topic><topic>Humans</topic><topic>Hydroxychloroquine - adverse effects</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Svensson, Markus</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Läkartidningen</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Svensson, Markus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potential harms associated with 4-aminoquinoline treatment</atitle><jtitle>Läkartidningen</jtitle><addtitle>Lakartidningen</addtitle><date>2020-04-23</date><risdate>2020</risdate><volume>117</volume><eissn>1652-7518</eissn><abstract>Hydroxychloroquine and chloroquine are currently being evaluated as treatment against COVID-19. These drugs are associated with some potential harms, including QTc-interval prolongation, hypoglycaemia, severe skin reactions and psychiatric effects. Use of hydroxychloroquine or chloroquine should be reserved to current indications or clinical trials, as recommended by several governmental medical products agencies.</abstract><cop>Sweden</cop><pmid>32365215</pmid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1652-7518 |
| ispartof | Läkartidningen, 2020-04, Vol.117 |
| issn | 1652-7518 |
| language | swe |
| recordid | cdi_pubmed_primary_32365215 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Aminoquinolines - adverse effects Aminoquinolines - therapeutic use Antimalarials - adverse effects Antiviral Agents - adverse effects Betacoronavirus Chloroquine - adverse effects Coronavirus Infections - drug therapy COVID-19 Humans Hydroxychloroquine - adverse effects Pandemics Pneumonia, Viral - drug therapy SARS-CoV-2 |
| title | Potential harms associated with 4-aminoquinoline treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T12%3A37%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potential%20harms%20associated%20with%204-aminoquinoline%20treatment&rft.jtitle=L%C3%A4kartidningen&rft.au=Svensson,%20Markus&rft.date=2020-04-23&rft.volume=117&rft.eissn=1652-7518&rft_id=info:doi/&rft_dat=%3Cpubmed%3E32365215%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32365215&rfr_iscdi=true |